Candesartan Cilexetil/Hydrochlorothiazide

坎地沙坦酯/氢氯噻嗪

Report date: 2022/12/16 14:36:17

Base Information

Drug NameCandesartan Cilexetil/Hydrochlorothiazide
Drug Alias Name坎地沙坦酯和氢氯噻嗪Candesartan Cilexetil-Hydrochlorothiazide mixt坎地沙坦/氢氯噻嗪Candesartan Cilexetil and HydrochlorothiazideHydrochlorothiazide/Candesartan Cilexetil +[15] 
ClassificationSmall molecules
Mechanisms of ActionThiazide-sensitive sodium-chloride cotransporter inhibitorsAngiotensin II Receptor Type 1 antagonists
TargetsThiazide-sensitive sodium-chloride cotransporterAngiotensin II Receptor Type 1
Therapy Area/IndicationsHypertension
Global Approved IndicationsHypertension
Approved Indications in ChinaHypertension
Original Approved Country/TerritoryUnited States
Original Approved Date2000/09/05
Country/TerritoryUnited StatesMainland ChinaJapan
CombinationsYes HydrochlorothiazideCandesartan Cilexetil
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAni Pharmaceuticals IncTakeda Pharmaceutical Co LtdJiangsu Deyuan Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHypertension
Inactive IndicationsN/A

Other Information

ATC CodeC09DA06
Related LinksKEGG